Cost-Effectiveness of Different Diagnostic Strategies in Suspected Stable Coronary Artery Disease in Portugal

António Miguel Ferreira1,2, Hugo Marques1,3,4, Pedro Araújo Gonçalves1,2,4, Nuno Cardim1,4
Hospital da Luz1, Lisboa; Hospital Santa Cruz - Centro Hospitalar de Lisboa Ocidental2, Lisboa; Hospital Santa Marta - Centro Hospitalar de Lisboa Central3, Lisboa; Faculdade de Ciências Médicas da Universidade Nova de Lisboa4, Lisboa — Portugal

Abstract

Background: Cost-effectiveness is an increasingly important factor in the choice of a test or therapy.

Objective: To assess the cost-effectiveness of various methods routinely used for the diagnosis of stable coronary disease in Portugal.

Methods: Seven diagnostic strategies were assessed. The cost-effectiveness of each strategy was defined as the cost per correct diagnosis (inclusion or exclusion of obstructive coronary artery disease) in a symptomatic patient. The cost and effectiveness of each method were assessed using Bayesian inference and decision-making tree analyses, with the pretest likelihood of disease ranging from 10% to 90%.

Results: The cost-effectiveness of diagnostic strategies was strongly dependent on the pretest likelihood of disease. In patients with a pretest likelihood of disease of ≤50%, the diagnostic algorithms, which include cardiac computed tomography angiography, were the most cost-effective. In these patients, depending on the pretest likelihood of disease and the willingness to pay for an additional correct diagnosis, computed tomography angiography may be used as a frontline test or reserved for patients with positive/inconclusive ergometric test results or a calcium score of >0. In patients with a pretest likelihood of disease of ≥60%, up-front invasive coronary angiography appears to be the most cost-effective strategy.

Conclusions: Diagnostic algorithms that include cardiac computed tomography angiography are the most cost-effective in symptomatic patients with suspected stable coronary artery disease and a pretest likelihood of disease of ≤50%. In high-risk patients (pretest likelihood of disease ≥60%), up-front invasive coronary angiography appears to be the most cost-effective strategy. In all pretest likelihoods of disease, strategies based on ischemia appear to be more expensive and less effective compared with those based on anatomical tests. (Arq Bras Cardiol. 2014; 102(4):391-402)

Keywords: Coronary disease / economics; Coronary disease / diagnosis; Cost-Benefit analysis.

Introduction

Clinical assessment of an individual with suspected stable coronary artery disease (CAD) is usually complemented by noninvasive tests such as the ergometric test (ET), myocardial perfusion scintigraphy (MPS), or stress echocardiography (StressEcho). Cardiac computed tomography angiography (CCTA) has broadened the options for the assessment of CAD patients and is a potentially beneficial alternative for individuals with an intermediate or a low pretest likelihood of disease (PLD)1. However, the generalized adoption of new techniques that, although appealing, may entail additional costs and no added value, should be considered carefully with regard to the increasing economic pressure to which healthcare systems are exposed. Therefore, it is important to determine the cost-effectiveness of diagnostic strategies routinely used for the diagnosis of stable CAD and identify patients for whom CCTA is a cost-effective alternative.

Methods

The cost-effectiveness of seven diagnostic strategies was assessed: (1) ET followed by MPS in positive or inconclusive cases, (2) ET followed by 64-detector CCTA in positive or inconclusive cases, (3) MPS (as first option), (4) StressEcho with dobutamine (as first option), (5) CCTA (as first option), (6) calcium scoring (CaSc) followed by CCTA (CACS-CCTA) when CaSc > 0, and (7) invasive coronary angiography (CATH) as the first and only test. All considered strategies presuppose the end of the diagnostic procedures when a test is negative and a confirmation CATH when the last test of the noninvasive strategy is positive or inconclusive. In addition, an eight alternative was assessed in individuals with a PLD of 10%, which involved not performing any complementary diagnostic tests and assuming the absence of obstructive CAD.
A decision-making tree analysis was performed according to the method described by Patterson et al.\(^2,3\) to assess the cost-effectiveness of each strategy according to PLD. In this method, hypothetical cohorts of patients with a certain PLD are subjected to each of the diagnostic strategies. Then, Bayesian inference is used to estimate the cost and effectiveness of each strategy according to the test characteristics. Sensitivity, specificity, and the rate of nondiagnostic tests were gathered from meta-analysis, clinical recommendations, and published series (Table 1). The rate of nondiagnostic ET and StressEcho tests was calculated as the mean percentage of patients who fail to reach the target heart rate. MPS was always considered to be diagnostic, and its accuracy was considered independent of the stress method used. In addition, CCTA tests were always considered diagnostic since the meta-analysis on its accuracy was performed on an intention-to-diagnose basis, assuming that all nondiagnostic tests would be false-positive, thereby decreasing the specificity of the test\(^4\). The sensitivity and specificity of CaSc > 0 for the diagnosis of obstructive CAD were obtained through combined analysis of the results of two international multicenter clinical trials\(^5,6\). We assumed that CATH tests would always be diagnostic, with a sensitivity and specificity of 100%.

### Comparison of cost-effectiveness

The cost-effectiveness of each strategy was defined as the cost per correct diagnosis (inclusion or exclusion of obstructive CAD) in a symptomatic patient. According to this definition, a lower cost value per correct diagnosis translates into better cost-effectiveness. Comparison between the diagnostic strategies was made from the society’s perspective (i.e., including all costs, regardless of the payer)\(^14\). To compare the incremental cost-effectiveness of each option with that of all the other alternatives, the diagnostic strategies were ranked in increasing order of cost and those outperformed by complete dominance (simultaneously more expensive and less effective) and incomplete dominance (less effective with a higher incremental cost-effectiveness ratio; ICER) were excluded. ICERs (added cost per additional correct diagnosis) were calculated for each strategy relative to the previous less expensive strategy.

### Definition of cost

The cost of a diagnostic strategy includes direct and indirect costs. Direct cost was considered as the cost of the examinations performed for patients in each cohort, using the current *Tabela de Preços do Serviço Nacional de Saúde* (price list of the National Health Service), which was defined by the Ordinance 839-A/2009 of July 31, 2009, as a reference\(^15\). The price of cardiac CCTA was defined as the sum of the values of CCTA, intravenous contrast supplement, and post-processing (Table 2). In the CaSc-CCTA strategy, a cost of € 80.00 was assumed (identical to that of noncontrast chest CT\(^\)) for patients who only underwent CaSc, while a cost of € 207.10 was assumed for those who also underwent CCTA.

### Table 1 – Sensitivity, specificity, and rate of nondiagnostic tests for each method as assumed in the economic model

|            | ET (%) | MPS (%) | StressEcho (%) | CCTA (%) | CACS > 0 (%) |
|------------|--------|---------|----------------|----------|--------------|
| Sensitivity| 68\(^1\) | 87\(^3,9\) | 88\(^10\) | 98\(^4\) | 93\(^5,6\)   |
| Specificity| 77\(^2\) | 81\(^11\) | 84\(^10\) | 85\(^4\) | 43\(^5,6\)   |
| Rate of nondiagnostic tests | 17\(^12\) | 0 | 18\(^13\) | 0\(^1\) | 0 |
The following indirect costs were included.

1. Cost associated with incidental findings during CaSc and cardiac CCTA. We assumed that 7% of these tests would exhibit incidental extracardiac findings of uncertain clinical significance, which would require direct investigation\(^6\), usually to assess lung nodules. We assumed that these cases would require noncontrast chest CT a few months later\(^7\) at an additional cost of £ 80.00\(^8\).

2. Cost associated with complications caused by diagnostic CATH. We assumed that the rate of major iatrogenic adverse cardiovascular events (death, myocardial infarction, or stroke) was 0.05%\(^9\), while that of vascular access-related complications that required transfusion or surgery was 0.4% (for a rate of 80% for radial access use)\(^9\). With regard to major cardiovascular events, we considered acute myocardial infarction to be a typical complication\(^10,11\) and estimated its cost by adding the cost for a homogeneous diagnostic group (HDG) of patients with nonfatal myocardial infarction without major complications (£3,671.53)\(^15\) to the cost of 1 month of temporary incapacity to work, for a gross domestic product (GDP) per capita of £16,100, assuming that half of the population assessed for suspected CAD was active. The mean cost of an iatrogenic major cardiovascular event thus estimated was £ 4,342. The mean cost of a vascular access complication requiring transfusion or surgery was estimated to be £1,500 (expert opinion).

3. Cost of false-negative tests. The potential cost of false-negative tests includes the cost of repeat tests for CAD diagnosis, other examinations for the differential diagnosis of chest pain, worse quality of life, and added risk for cardiovascular events due to the non-prescription of adequate medical therapy. These costs are particularly difficult to evaluate. Previous studies have used various methods to estimate that the cost of a false-negative test is 1.4–6.7 times higher than that of a false-positive test\(^1,12,13\). Therefore, false-negative tests were allocated a cost that was three times higher than that of a false-positive test (£1,818 for each false-negative test). In the scenario where no further testing is performed assuming the absence of CAD (a hypothesis considered for patients with PLD of 10%), the costs of false-negatives were the only ones taken into account.

We did not include the cost of complications caused by noninvasive tests in the model because serious complications resulting from these tests are very rare and would only marginally increase costs. In addition, the cost associated with potential exposure to ionizing radiation was not included because this was a short-term cost-effectiveness model; furthermore, there is great uncertainty about the effects of radiation doses used in these tests\(^14,15\).

Sensitivity analysis

To assess the extent to which the results obtained depended on some of the variables under study, several sensitivity analyses were performed. Calculations were repeated using new assumptions such as decreasing the sensitivity and specificity values for cardiac CCTA to 96% and 81%, respectively (lower limits of 95% confidence intervals in the meta-analysis of 53 studies)\(^16\), decreasing the cost of MPS to £207.10 (equating the cost of MPS with that of CCTA), decreasing the rate of inconclusive StressEcho tests to 5%, and assuming zero cost for false-negative tests.

Results

Figure 1 shows the cost-effectiveness plans for the diagnostic strategies for each scenario of PLD. In general, costs increase and the percentage of correct diagnosis decreases with increasing PLD (due to the increase in the number of false-negative tests).

The composition of direct and indirect costs is shown in Table 3 (simulation of the expected results when a cohort of 100 patients with a PPT of 30% is assessed).

Table 4 summarizes the results of incremental cost-effectiveness of the diagnostic strategies applied to hypothetical cohorts of 100 patients with a PLD of 10%–90%. Diagnostic strategies were presented in increasing order of cost and respective ICER for each assessed PLD. In all scenarios of PLD, the diagnostic strategies for ET-MPS, MPS, and StressEcho are dominated by alternative strategies that are less expensive and more effective. According to the cost-effectiveness criterion, choosing the best diagnostic strategy depends on the percentage of false-negative tests that one is willing to accept and on the willingness to pay for an additional correct diagnosis (Figure 2). For example, for a limit of £5,000 per additional correct diagnosis, the preferred strategy would be CACS-CCTA for patients with a PLD of 10%, CCTA for those with a PLD of 20%–40%, and CATH for those with a PLD of ≥50%.

Results of sensitivity analysis

To assess the robustness of the results and the influence of several assumptions, we reformulated the model by altering some parameters such as diagnostic accuracy of CCTA, price of MPS, rate of inconclusive StressEcho tests, and cost of false-negative tests.

The decrease in sensitivity and specificity of CCTA to 96% and 81%, respectively, resulted in the increase in total cost and ICER of the strategies that include CCTA. Nevertheless, the ET-MPS, MPS, and StressEcho diagnostic strategies remained dominated, with the increasing order of cost-effectiveness shown in Table 4 being maintained for every assessed PLD.

When the cost of MPS is equated to the cost of CCTA (£ 207.10), the cost-effectiveness of the ET-MPS and MPS diagnostic strategies improves. However, these strategies remained dominated by other diagnostic methods (less expensive and more effective) for all assessed PLDs (Table 5).

The decrease in the rate of inconclusive StressEcho tests from 18% to 5% resulted in the improvement of its cost-effectiveness; however, this method remained dominated by other diagnostic strategies for all the assessed PLDs. When the StressEcho strategy was compared with the dominant noninvasive strategies (more cost-effective), at each level of PLD, the StressEcho strategy entailed an additional cost of £303 to £2,700 per 100 patients, along with an increase in false-negative tests from 1.1% to 5.7%.

In the model where the absence of indirect costs is assumed in patients with false-negative tests, the ET-CCTA strategy is the least expensive for all levels of PLD. However, this diagnostic procedure resulted in a significant number of false-negative tests, particularly for intermediate or high PLDs. The transition to more effective strategies becomes less expensive with the increasing prevalence of obstructive CAD (Table 6).
Discussion

In recent years, the need to consider the cost of clinical decisions is becoming increasingly important. Cost-effectiveness analyses allow for more efficient use of health resources and rationalize the use of new technologies, often more expensive than their alternatives. To our knowledge, this is the first assessment of the cost-effectiveness of several strategies used for the diagnosis of stable CAD in Portugal. The results of this analysis indicate that, in this country, diagnostic algorithms that include cardiac CCTA are the most cost-effective methods in symptomatic patients with suspected obstructive CAD and a PLD of ≤ 50%. In high-risk patients (PLD > 50%), immediate CATH appears to be the most cost-effective strategy. The model suggests that ischemia imaging techniques (MPS and StressEcho) are more expensive and less effective compared with other diagnostic strategies for all assessed PLDs. With regard to patients with a PLD of ≤ 50% and the conservative scenario wherein the willingness to pay for an additional correct diagnosis is €1,000, the results of incremental cost-effectiveness indicate that it is advantageous to perform an ergometric test before CCTA in patients with a lower PLD (10%), do a “rule-out” CaSc before CCTA in patients with a PLD of 20–30%, and perform up-front CCTA in patients with a PLD of 40–50%. In the more liberal scenario (willingness to pay €5,000 for an additional correct diagnosis), the preferred strategy would be SCa-CCTA for patients with a PLD of 10%, CCTA for patients with a PLD of 20–40%, and CATH for patients with a PLD of ≥ 50%.
Table 3 – Results of cost-effectiveness of the diagnostic strategies for 100 patients with a pretest likelihood of disease of 30%

| After non-invasive testing          | ET-MPS | ET-CCTA | MPS   | StressEcho | CCTA | CACS-CCTA | CATH |
|-------------------------------------|--------|---------|-------|------------|------|-----------|------|
| True positive                       | 19.2   | 21.6    | 26.1  | 21.2       | 29.4 | 27.4      | -    |
| False positive                      | 4.8    | 3.8     | 13.3  | 9.2        | 10.5 | 6.0       | -    |
| True negative                       | 65.2   | 66.2    | 56.7  | 48.2       | 59.5 | 64.0      | -    |
| False negative                      | 10.8   | 8.4     | 3.9   | 3.4        | 0.6  | 2.6       | -    |
| Inconclusive                        | 0      | 0       | 0     | 18         | 0    | 0         | -    |
| Invasive Angiographies              | 24     | 25.4    | 39.4  | 48.4       | 39.9 | 33.4      | 100  |
| Normal invasive Angiographies       | 4.8 (20%) | 3.8 (15%) | 13.3 (34%) | 21.8 (45%) | 10.5 (26%) | 6 (18%) | 70 (70%) |
| Correct diagnoses                   | 89.2   | 91.6    | 96.1  | 96.6       | 99.4 | 97.4      | 100  |

| Costs                               |        |        |       |            |      |           |      |
|-------------------------------------|--------|--------|-------|------------|------|-----------|------|
| Noninvasive tests                   | € 23.752 | € 13.475 | € 42.440 | € 12.180  | € 20.710 | € 16.642 |  -   |
| CATH                                | € 14.033 | € 14.860 | € 23.069 | € 28.303  | € 23.362 | € 19.543 | € 58.550 |
| CATH complications de CATH          | € 318   | € 337   | € 523  | € 643      | € 530  | € 443     | € 1.327 |
| Incidental findings                 | -      | € 265   | -     | € 560      | € 560  | -         |      |
| False-negative tests                | € 19.693 | € 15.287 | € 7.090 | € 6.261   | € 1.091 | € 4.785  | -    |
| Total cost                          | € 57.796 | € 44.224 | € 73.122 | € 47.386  | € 46.252 | € 41.973 | € 59.877 |
| Cost per correct diagnosis          | € 648   | € 483   | € 761  | € 491      | € 465  | € 431     | € 599 |

ET: ergometric test, MPS: myocardial perfusion scintigraphy, CCTA: computed tomography angiography of the coronary arteries, StressEcho: stress echocardiography with dobutamine, CACS: calcium score, CATH: invasive coronary angiography.

Ultimately, the selection of a diagnostic method on the basis of cost-effectiveness criteria depends on PLD and the willingness to pay for an additional correct diagnosis. Contrary to long-term cost-effectiveness studies, in this context, there is no commonly accepted cost-effectiveness limit (for example: € 30,000/quality-adjusted life-years (QALY)) to serve as a reference for the adoption or rejection of a diagnostic strategy. However, a recent study suggested that, for a CAD prevalence of ≥30%, values of incremental cost per correct diagnosis in the short-term model are similar to those of incremental cost per QALY estimated in long-term models. In a more conservative scenario, the willingness of the Portuguese society to pay for an additional correct diagnosis will be at least ≥ €1.010, which corresponds to the sum of the direct costs of MPS followed by CATH, a diagnostic strategy that is well accepted and frequently used in Portugal.

Of the scenarios assessed in the sensitivity analysis, the one in which CCTA and MPS have the same price is particularly important because this is the case in some countries. Even in this scenario, MPS remains a dominated strategy (i.e., more expensive and less effective) because it is less accurate than CCTA, particularly in terms of sensitivity. The results would only be different in a scenario (not tested) where the price of scintigraphy was identical and where scintigraphy was more accurate.

In general, these results are in line with those obtained in other countries that consider cardiac CCTA as a cost-effective method for the diagnosis or exclusion of obstructive CAD in patients with an intermediate PLD. This is probably because of a favorable combination of cost (relatively affordable) and accuracy. Better diagnostic accuracy simultaneously increases the denominator of the cost-effectiveness equation (number of correct diagnoses) and decreases the numerator, with lower indirect costs from false-negative and false-positive tests.

The interpretation of these results and analysis of their potential implications should consider several factors. First, it should be noted that the cost-effectiveness of diagnostic strategies is critically dependent on the adequate selection of patients. The calculation of PLD is a key step in selecting a cost-effective diagnostic strategy. This assessment can be easily and quickly made using validated clinical scores that were recently calibrated in European contemporary populations. Second, the results of this analysis only apply to patients without known CAD. Therefore, these findings do not mean that functional tests are not useful or cost-effective in distinct contexts, namely in patients with established CAD. In the latter case, the performance of CCTA is suboptimal, and the key issues are the presence or absence of ischemia and the localization, extension, and severity of ischemia. Rather than seeing these results in terms of winners and losers, it is important to know the advantages and disadvantages of...
Table 4 – Incremental cost-effectiveness of the diagnostic strategies applied to hypothetical cohorts of 100 patients with a PLD of 10%–60%. For a PLD of >=60%, all strategies are dominated by the CATH strategy.

| Pretest likelihood | Diagnostic strategy | Total cost (£) | Number of correct diagnoses* | False-negative tests* | ICER** |
|-------------------|---------------------|---------------|-----------------------------|----------------------|--------|
| 10%               | No test             | 18.180        | 90.0                        | 10.0                 | -      |
|                   | ET-CCTA             | 24.473        | 97.2                        | 2.8                  | € 874  |
|                   | CACS-CCTA           | 27.975        | 99.1                        | 0.9                  | € 1.819|
|                   | ET-MPS              | 34.667        | 96.4                        | 3.6                  | Dominated|
|                   | CCTA                | 35.585        | 99.8                        | 0.2                  | € 11.234|
|                   | StressEcho          | 36.338        | 96.9                        | 1.1                  | Dominated|
|                   | CATH                | 59.877        | 100                         | 0                    | € 121.461|
|                   | MPS                 | 60.252        | 98.7                        | 1.3                  | Dominated|
|                   | ET-CCTA             | 34.349        | 94.4                        | 5.6                  | -      |
|                   | CACS-CCTA           | 34.974        | 96.2                        | 1.8                  | € 162  |
|                   | CCTA                | 40.918        | 99.6                        | 0.4                  | € 4.388|
|                   | StressEcho          | 41.862        | 97.7                        | 2.3                  | Dominated|
|                   | ET-MPS              | 46.232        | 92.8                        | 7.2                  | Dominated|
|                   | CATH                | 59.877        | 100                         | 0                    | € 47.397|
|                   | MPS                 | 66.687        | 97.4                        | 2.6                  | Dominated|
|                   | ET-CCTA             | 44.224        | 91.6                        | 8.4                  | Dominated|
|                   | CACS-CCTA           | 41.973        | 97.4                        | 2.6                  | -      |
|                   | CCTA                | 51.585        | 99.2                        | 0.8                  | € 964  |
|                   | StressEcho          | 52.910        | 95.4                        | 4.6                  | Dominated|
|                   | ET-MPS              | 54.099        | 88.8                        | 11.2                 | Dominated|
|                   | CATH                | 59.877        | 100                         | 0                    | € 10.365|
|                   | MPS                 | 73.122        | 96.1                        | 3.9                  | Dominated|
|                   | CACS-CCTA           | 48.972        | 96.5                        | 3.5                  | -      |
|                   | CCTA                | 51.585        | 99.2                        | 0.6                  | € 2.106|
|                   | StressEcho          | 52.910        | 95.4                        | 4.6                  | Dominated|
|                   | ET-MPS              | 54.099        | 88.8                        | 11.2                 | Dominated|
|                   | CATH                | 59.877        | 100                         | 0                    | € 10.365|
|                   | MPS                 | 75.557        | 94.8                        | 5.2                  | Dominated|
|                   | CACS-CCTA           | 55.971        | 95.6                        | 4.4                  | -      |
|                   | CCTA                | 56.919        | 99.0                        | 1.0                  | € 280  |
|                   | StressEcho          | 58.434        | 94.3                        | 6.7                  | Dominated|
|                   | CATH                | 59.877        | 100                         | 0                    | € 2.959|
|                   | ET-MPS              | 63.975        | 86.0                        | 14.0                 | Dominated|
|                   | MPS                 | 85.992        | 93.5                        | 6.5                  | Dominated|
| 20%               | CATH                | 59.877        | 100                         | 0                    | € 2.959|
|                   | CCTA                | 62.252        | 98.8                        | 1.9                  | Dominated|
|                   | StressEcho          | 62.970        | 94.7                        | 5.3                  | Dominated|
|                   | ET-MPS              | 63.958        | 93.1                        | 6.9                  | Dominated|
|                   | MPS                 | 92.427        | 92.2                        | 7.8                  | Dominated|
|                   | ET-MPS              | 92.490        | 78.3                        | 21.7                 | Dominated|
| 30%               | CATH                | 59.877        | 100                         | 0                    | € 2.959|
|                   | CCTA                | 62.252        | 98.8                        | 1.9                  | Dominated|
|                   | StressEcho          | 62.970        | 94.7                        | 5.3                  | Dominated|
| 40%               | CATH                | 59.877        | 100                         | 0                    | € 2.959|
|                   | CCTA                | 62.252        | 98.8                        | 1.9                  | Dominated|
|                   | StressEcho          | 62.970        | 94.7                        | 5.3                  | Dominated|
| 50%               | CATH                | 59.877        | 100                         | 0                    | € 2.959|
|                   | CCTA                | 62.252        | 98.8                        | 1.9                  | Dominated|
|                   | StressEcho          | 62.970        | 94.7                        | 5.3                  | Dominated|
| 60%               | CATH                | 59.877        | 100                         | 0                    | € 2.959|
|                   | CCTA                | 62.252        | 98.8                        | 1.9                  | Dominated|
|                   | StressEcho          | 62.970        | 94.7                        | 5.3                  | Dominated|

*At the end of the diagnostic strategy, i.e., including the results of CATH when the noninvasive tests are positive or inconclusive ** Incremental cost per additional correct diagnosis. ICER: incremental cost-effectiveness ratio (Δ cost/Δ correct diagnosis), ET: ergometric test, CCTA: computed tomography angiography of the coronary arteries, CaSc: calcium scoring, MPS: myocardial perfusion scintigraphy, StressEcho: stress echocardiography
the anatomical and functional methods in different contexts. Third, it should be acknowledged that the exclusive use of anatomical methods for the diagnosis of obstructive CAD carries some risks, namely the hazard of prompting unnecessary revascularizations. However, CATH, in the assessed strategies, had a diagnostic and not necessarily therapeutic objective (as in the COURAGE study)\(^3\), and although both coronary angiographies (invasive or CT) essentially provide anatomical information, there is a possibility of complementing this assessment with functional information provided by coronary fraction flow reserve (FFR) measurement, which is emerging as the gold-standard and has been demonstrated to be cost-effective\(^3\). It is probable that, in the near future, CCTA will allow the assessment of ischemia using perfusion techniques\(^3\) or virtual CFR measurements\(^3\); however, this is not yet an established procedure.

Limitations

This study has some limitations. First, it described a theoretical model, the results of which are dependent on factors such as sensitivity and specificity of various techniques that, in the real world, can be different from those reported in international studies of reference. With regard to CCTA, it should be noted that its specificity depends on PLD because of the varying prevalence of coronary calcifications. The use of intermediate values may have led to the underestimation of the cost-effectiveness of CCTA in patients with a lower PLD and overestimation in patients with a higher PLD\(^3\). Similarly, like in all analyses of this type, the results are only applicable to patients who are capable of undergoing any of the tests under study (i.e., able to exercise, without complete block of the left bundle branch, without severe renal impairment, and not allergic to iodinated contrast medium). We chose to exclude the costs and benefits related to periods after the diagnosis phase (such as costs of medication, revascularization, hospitalization, and possible gains in QALY) in the model because they entail greater complexity and uncertainty. However, there is evidence that the diagnosis of obstructive CAD (vs. false-negative tests) is associated with an increase of three QALYs over a period of 10 years\(^3\). Depending on the assumptions made, it is possible that long-term analysis produces results that are significantly different from those obtained in this analysis. In addition, to avoid a more complex analysis, not all possible diagnostic strategies were considered; we chose accessible and frequently utilized modalities and diagnostic procedures. Moreover, conclusive tests were classified as positive or negative, in a reductionist dichotomization which is inevitable in this type of analysis. Finally, cost-effectiveness should be one of the criteria considered in clinical decision-making. Other patient-related or context-

Figure 2 – Choice of the most cost-effective diagnostic strategy according to the PLD and willingness to pay for a correct diagnosis. Once the maximum value that society is willing to pay for an additional correct diagnosis is established, the strategy that represents the best use of these resources is the one that intercepts the line of the value that society is willing to pay. For example, for a willingness to pay €1,500 per additional correct diagnosis, the best method would be ET-CCTA when the pretest likelihood of disease is 10%, CACS-CCTA when the pretest likelihood is 20%–30%, CCTA when the pretest likelihood is 40%–50%, and CATH when the pretest likelihood is ≥60%.
### Table 5 – Incremental cost-effectiveness of diagnostic strategies in hypothetical cohorts of 100 patients with a PLD of 10%–60%, considering identical prices for MPS and CCTA of the coronary arteries. For a PLD of ≥60%, all strategies were dominated by CATH

| Pretest likelihood | Diagnostic strategy | Total cost (€) | Number of correct diagnoses* | False-negative tests* | ICER** |
|--------------------|---------------------|----------------|-----------------------------|-----------------------|--------|
| 10%                | No test             | 18.180         | 90.0                        | 10.0                  | -      |
|                    | ET-CCTA             | 24.473         | 97.2                        | 2.8                   | €874   |
|                    | ET-MPS              | 26.013         | 96.4                        | 3.6                   | Dominated |
|                    | CACS-CCTA           | 27.975         | 99.1                        | 0.9                   | €1,819 |
|                    | CCTA                | 35.585         | 99.8                        | 0.2                   | €11,234 |
|                    | StressEcho          | 36.338         | 98.9                        | 1.1                   | Dominated |
|                    | MPS                 | 38.522         | 98.7                        | 1.3                   | Dominated |
|                    | CATH                | 59.877         | 100                         | 0                     | €121,461 |
|                    | ET-CCTA             | 34.349         | 94.4                        | 5.6                   | -      |
|                    | CACS-CCTA           | 34.974         | 98.2                        | 1.8                   | €162   |
|                    | TET-MPS             | 36.766         | 92.8                        | 7.2                   | Dominated |
|                    | CCTA                | 40.918         | 99.6                        | 0.4                   | €4,388 |
|                    | StressEcho          | 41.862         | 97.7                        | 2.3                   | Dominated |
|                    | MPS                 | 44.957         | 97.4                        | 2.6                   | Dominated |
|                    | CATH                | 59.877         | 100                         | 0                     | €47,397 |
|                    | CACS-CCTA           | 41.973         | 97.4                        | 2.6                   | -      |
|                    | ET-CCTA             | 44.224         | 91.6                        | 8.4                   | Dominated |
|                    | CCTA                | 46.252         | 99.4                        | 0.6                   | €2,106 |
|                    | StressEcho          | 47.386         | 96.6                        | 3.4                   | Dominated |
|                    | ET-MPS              | 47.519         | 89.2                        | 10.8                  | Dominated |
|                    | MPS                 | 51.392         | 96.1                        | 3.9                   | Dominated |
|                    | CATH                | 59.877         | 100                         | 0                     | €22,709 |
|                    | CACS-CCTA           | 48.972         | 96.5                        | 3.5                   | -      |
|                    | CCTA                | 51.585         | 99.2                        | 0.8                   | €964   |
|                    | StressEcho          | 52.910         | 95.4                        | 4.6                   | Dominated |
|                    | ET-CCTA             | 54.099         | 88.8                        | 11.2                  | Dominated |
|                    | MPS                 | 57.827         | 94.8                        | 5.2                   | Dominated |
|                    | ET-MPS              | 58.272         | 85.6                        | 14.4                  | Dominated |
|                    | CATH                | 59.877         | 100                         | 0                     | €10,365 |
|                    | CACS-CCTA           | 55.971         | 95.6                        | 4.4                   | -      |
|                    | CCTA                | 56.919         | 99.0                        | 1.0                   | €280   |
|                    | StressEcho          | 58.434         | 94.3                        | 6.7                   | Dominated |
|                    | CATH                | 59.877         | 100                         | 0                     | €2,959 |
|                    | ET-CCTA             | 63.975         | 86.0                        | 14.0                  | Dominated |
|                    | MPS                 | 64.262         | 93.5                        | 6.5                   | Dominated |
|                    | ET-MPS              | 69.025         | 82.0                        | 18.0                  | Dominated |
|                    | CATH                | 59.877         | 100                         | 0                     | -      |
|                    | CACS-CCTA           | 62.252         | 98.8                        | 1.9                   | Dominated |
|                    | CCTA                | 62.970         | 94.7                        | 5.3                   | Dominated |
|                    | StressEcho          | 63.958         | 93.1                        | 6.9                   | Dominated |
|                    | MPS                 | 70.697         | 92.2                        | 7.8                   | Dominated |
|                    | ET-CCTA             | 73.850         | 83.2                        | 16.8                  | Dominated |
|                    | ET-MPS              | 79.778         | 78.3                        | 21.7                  | Dominated |

* At the end of the diagnostic strategy, i.e., including the results of CATH when the noninvasive tests are positive or inconclusive. ** Incremental cost per additional correct diagnosis. ICER: incremental cost-effectiveness ratio (Δ cost/Δ correct diagnosis), ET: ergometric test, CCTA: computed tomography angiography of the coronary arteries, CaSc: calcium scoring, MPS: myocardial perfusion scintigraphy, StressEcho: stress echocardiography


Table 6 – Incremental cost-effectiveness of diagnostic strategies in hypothetical cohorts of 100 patients with a PLD of 10%–90%, considering zero cost for false-negative tests. The dominated strategies are not shown

| Pretest likelihood | Diagnostic strategy | Total cost (€) | Number of correct diagnoses* | False-negative tests* | ICER** (€) |
|--------------------|---------------------|---------------|------------------------------|-----------------------|------------|
| 10%                | ET-CCTA             | 19.378        | 97.2                         | 2.8                   | -          |
|                    | CACS-CCTA           | 26.379        | 99.1                         | 0.9                   | 3.637      |
|                    | CCTA                | 35.221        | 99.8                         | 0.2                   | 13.052     |
|                    | CATH                | 59.877        | 100                          | 0                     | 123.279    |
| 20%                | ET-CCTA             | 24.157        | 94.4                         | 5.6                   | -          |
|                    | CACS-CCTA           | 31.783        | 98.2                         | 1.8                   | 1.980      |
|                    | CCTA                | 40.191        | 99.6                         | 0.4                   | 6.206      |
|                    | CATH                | 59.877        | 100                          | 0                     | 49.215     |
| 30%                | ET-CCTA             | 28.937        | 91.6                         | 8.4                   | -          |
|                    | CACS-CCTA           | 37.187        | 97.4                         | 2.6                   | 1.428      |
|                    | CCTA                | 45.161        | 99.4                         | 0.6                   | 3.924      |
|                    | CATH                | 59.877        | 100                          | 0                     | 24.527     |
| 40%                | ET-CCTA             | 33.717        | 88.8                         | 11.2                  | -          |
|                    | CACS-CCTA           | 42.591        | 96.5                         | 3.5                   | 1.152      |
|                    | CCTA                | 50.131        | 99.2                         | 0.8                   | 2.782      |
|                    | CATH                | 59.877        | 100                          | 0                     | 12.183     |
| 50%                | ET-CCTA             | 38.496        | 86.0                         | 14.0                  | -          |
|                    | CACS-CCTA           | 47.995        | 95.6                         | 4.4                   | 987        |
|                    | CCTA                | 55.101        | 99.0                         | 1.0                   | 2.098      |
|                    | CATH                | 59.877        | 100                          | 0                     | 4.777      |
| 60%                | ET-CCTA             | 37.581        | 83.4                         | 16.6                  | -          |
|                    | StressEcho          | 51.435        | 93.1                         | 6.9                   | 822        |
|                    | CACS-CCTA           | 53.399        | 94.7                         | 5.3                   | 1.210      |
|                    | CATH                | 59.877        | 100                          | 0                     | 1.231      |
| 70%                | ET-CCTA             | 48.059        | 80.4                         | 19.6                  | -          |
|                    | StressEcho          | 54.872        | 92.0                         | 8.0                   | 588        |
|                    | CATH                | 59.877        | 100                          | 0                     | 623        |
| 80%                | ET-CCTA             | 52.836        | 77.6                         | 22.4                  | -          |
|                    | CATH                | 59.877        | 100                          | 0                     | 314        |
| 90%                | ET-CCTA             | 57.615        | 74.8                         | 25.2                  | -          |

* At the end of the diagnostic strategy, i.e., including the results of CATH when the noninvasive tests are positive or inconclusive. ** Incremental cost per additional correct diagnosis. ICER: incremental cost-effectiveness ratio (Δ cost/Δ correct diagnosis). ET: ergometric test. CCTA: computed tomography angiography of the coronary arteries. CaSc: calcium scoring. MPS: myocardial perfusion scintigraphy. StressEcho: stress echocardiogram with dobutamine.

related factors (availability, experience, etc.) should be considered during the selection of a complementary diagnosis method.

Conclusions

The diagnostic algorithms that include cardiac CCTA are the most cost-effective in symptomatic patients with suspected stable coronary disease and a PLD of ≤50%. In these patients, depending on the PLD and the willingness to pay per correct diagnosis, CCTA may be used as a first-line test or reserved for patients with positive/inconclusive ergometric test results or CaSC > 0. In high-risk patients (PLD ≥ 60%), immediate CATH appears to be the most cost-effective strategy. For all PLDs, strategies based on ischemia tests appear to be more expensive and less effective compared with strategies based on anatomical tests.
Author contributions

Conception and design of the research; Writing of the manuscript; Analysis and interpretation of the data and Critical revision of the manuscript for intellectual content: Gonçalves PA, Cardim N, Marques H, Ferreira AM. Acquisition of data and Statistical analysis: Ferreira AM.

Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

References

1. Taylor AJ, Cerqueira M, Hodgson JM, Mark D, Min J, O’Gara P, et al. ACCF/SCCT/ACR/AHA/ASE/ASCN/NASCI/SCAI/SCMR 2010 Appropriate Use Criteria for Cardiac Computed Tomography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. J Cardiovasc Comput Tomogr. 2010;4(6):407-433.

2. Patterson RE, Eng C, Horowitz SF, Gorlin R, Goldstein SR. Bayesian comparison of cost-effectiveness of different clinical approaches to diagnose coronary artery disease. J Am Coll Cardiol. 1984;4(2):278-289.

3. Patterson RE, Eisner RL, Horowitz SF. Comparison of cost-effectiveness and utility of exercise ECG, single photon emission computed tomography, positron emission tomography, and coronary angiography for diagnosis of coronary artery disease. Circulation. 1995;91(1):54-65.

4. Ollendorf DA, Kuba M, Pearson SD. The diagnostic performance of multi-slice coronary computed tomographic angiography: a systematic review. J Gen Intern Med. 2011;26(3):307-316.

5. Gottlieb I, Miller JM, Arbab-Zadeh A, Dewey M, Clouse ME, Sara L, et al. The absence of coronary calcium does not exclude obstructive coronary artery disease or the need for revascularization in patients referred for conventional coronary angiography. J Am Coll Cardiol. 2010;55(7):627-634.

6. Budoff MJ, Jollis JG, Dowd D, Min J, Group VCTS. Diagnostic accuracy of coronary artery calcium for obstructive disease: results from the ACCURACY trial. Int J Cardiol. 2013;166(2):505-8.

7. Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation. 2002;106(14):1883-92.

8. Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer J V, Berman DS, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging—executive summary: a report of the American College of Cardiology/American Heart Association Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). J Am Coll Cardiol. 2003;42(7):1318-33.

9. Heijenbrok-Kal MH, Fleischmann KE, Hunink MG. Stress echocardiography, stress single– photon–emission computed tomography and electron beam computed tomography for the assessment of coronary artery disease: a meta-analysis of diagnostic performance. Am Heart J. 2007;154(3):415-23.

10. Sicari R, Nihoyannopoulos P, Evangelista A, Kasprzak J, Lancellotti P, Poldermans D, et al. Stress Echocardiography Expert Consensus Statement - Executive Summary: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur Heart J. 2009;30(3):278-89.

11. Hendel RC, Conti CR, Callister TW, DePuey EG, Garcia EV, Bateman TM. The value and practice of attenuation correction for myocardial perfusion SPECT imaging: a joint position statement from the American Society of Nuclear Cardiology and the Society of Nuclear Medicine. J Nucl Cardiol. 2002;9(1):135-43.

12. Myers J, Prakash M, Froelicher V, Du D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med. 2002;346(11):793-801.

13. Haworth MA, John AM, Malhotra R, Hung J, Raggi P, Picard MH. Quality assessment in dobutamine stress echocardiography: what are the clinical predictors associated with a non-diagnostic test? Cardiol Res. 2012;3(2):73-9.

14. World Health Organization. (WHO). Making choices in health: WHO guide to cost-effectiveness analysis. [Accessed in 2012 Jan 10]. Available from: http://www.who.int/choice/book/en

15. Serviço Nacional de Saúde. Portaria 839-A/2009 de 31 de julho de 2009. [Acesso em 2013 jul 15]. Disponível em http://www.dre.pt/cgi/dr/s.exe

16. Machaalyan J, Yam Y, Ruddy TD, Abraham A, Chen L, Beanlands RS, et al. Potential clinical and economic consequences of noncardiac incidental findings on cardiac computed tomography. J Am Coll Cardiol. 2009;54(16):1533-41.

17. Min JK, Gilmore A, Budoff MJ, Berman DS, O’Day K. Cost-effectiveness of coronary CT angiography versus myocardial perfusion SPECT for evaluation of patients with chest pain and no known coronary artery disease. Radiology. 2010;254(3):801-8.

18. Hamm CW, Albrecht A, Bonzel T, Kelm M, Lange H, Schachinger V, et al. [Diagnostic heart catheterization]. Clin Res Cardiol. 2008;97(8):475-512. Erratum in Clin Res Cardiol. 2008;97(12):925.

19. Jolly SS, Amlani S, Hamon M, Yusuf S, Mehta SR. Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. Am Heart J. 2009;157(1):132-40.

20. Dewey M, Hamn B. Cost-effectiveness of coronary angiography and calcium scoring using CT and stress MRI for diagnosis of coronary artery disease. Eur Radiol. 2007;17(5):1301-9.

21. Dorenkamp M, Bonaventura K, Sohns C, Becker CR, Leber AW. Direct costs and cost-effectiveness of dual-source computed tomography and invasive coronary angiography in patients with an intermediate pretest likelihood for coronary artery disease. Heart. 2012;98(6):606-7.

22. Kaufmann PA, Knuuti J. Ionizing radiation risks of cardiac imaging: estimates of the immeasurable. Eur Heart J. 2011;32(3):269-71.

23. Moattar G, Vale L, Brazzelli M, Hernandez R, Murray A, Scott N, et al. Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction. Health Technol Assess. 2004;8(30):iii-ix, 1-207.
24. Ladapo JA, Jaffer FA, Hofmann U, Thomson CC, Bamberg F, Dec W, et al. Clinical outcomes and cost-effectiveness of coronary computed tomography angiography in the evaluation of patients with chest pain. J Am Coll Cardiol. 2009;54(25):2409-22.

25. Kreisz FP, Merlin T, Moss J, Atherton J, Hiller JE, Gericke CA. The pre-test risk stratified cost-effectiveness of 64-slice computed tomography coronary angiography in the detection of significant obstructive coronary artery disease in patients otherwise referred to invasive coronary angiography. Heart Lung Circ. 2009;18(3):200-7.

26. Amemiya S, Takao H. Computed tomographic coronary angiography for diagnosing stable coronary artery disease: a cost-utility and cost-effectiveness analysis. Circ J. 2009;73(7):1263-70.

27. Mowatt G, Cummins E, Waugh N, Walker S, Cook J, Jia X, et al. Systematic review of the clinical effectiveness and cost-effectiveness of 64-slice or higher computed tomography angiography as an alternative to invasive coronary angiography in the investigation of coronary artery disease. Health Technol Assess. 2008;12(17):iii-vi, iv-143.

28. National Institute for Health and Clinical Excellence 2010 (NICE). Chest pain of recent onset - assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin. NICE clinical guidelines, March 2010. [Accessed in 2013 Nov 7]. Available from http://publications.nice.org.uk/chest-pain-of-recent-onset-cg95

29. Genders TS, Ferket BS, Dedic A, Galema TW, Mollet NR, de Feyter PJ, et al. Coronary computed tomography versus exercise testing in patients with stable chest pain: comparative effectiveness and costs. Int J Cardiol. 2013;167(4):1268-75.

30. Genders TS, Steyerberg EW, Alkadhi H, Leschka S, Desbiolles L, Nieman K, et al. A clinical prediction rule for the diagnosis of coronary artery disease: validation, updating, and extension. Eur Heart J. 2011;32(11):1316-30.

31. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503-16.

32. Fearon WF, Yeung AC, Lee DP, Yock PG, Heidenreich PA. Cost-effectiveness of measuring fractional flow reserve to guide coronary interventions. Am Heart J. 2003;145(5):882-7.

33. Ko BS, Cameron JD, Defrance T, Seneviratne SK. CT stress myocardial perfusion imaging using multidetector CT: a review. J Cardiovasc Comput Tomogr. 2011;5(6):345-56.

34. Koo BK, Erglis A, Doh JH, Daniels DV, Jegere S, Kim HS, et al. Diagnosis of ischemia-causing coronary stenoses by noninvasive fractional flow reserve computed from coronary computed tomographic angiograms. Results from the prospective multicenter DISCOVER-FLOW (Diagnosis of Ischemia-Causing Stenoses Obtained Via Noninvasive Fractional Flow Reserve) study. J Am Coll Cardiol. 2011;58(19):1989-97.

35. Min JK, Leipsic J, Pencina MJ, Berman DS, Koo BK, van Mieghem C, et al. Diagnostic accuracy of fractional flow reserve from anatomic CT angiography. JAMA. 2012;308(12):1237-45.

36. Meijboom WB, van Mieghem CA, Mollet NR, Pugliese F, Westink AC, van Pelt N, et al. 64-slice computed tomography coronary angiography in patients with high, intermediate, or low pretest probability of significant coronary artery disease. J Am Coll Cardiol. 2007;50(15):1469-75.
Ferreira et al.
Cost-effectiveness of coronary disease diagnosis

Original Article